LibrarianMeg said:

Orforglipron is the more interesting oral story because it is not a peptide at all.

I do not accept that the fasting window is a minor inconvenience. Adherence data on daily orals with timing requirements is consistently worse than weekly injections, and a drug you take imperfectly is a lower dose than the one on the box.

One concrete data point for the thread. Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a trend.

That is the short version; the long version is somebody else's post.

COA_Karl said:

I do not accept that the fasting window is a minor inconvenience.

Coming at COA_Karl’s question from a different direction. Most of what circulates confidently in this community traces back to one summary of one study, and the qualifier was dropped somewhere in the third retelling.

Following on from TinaHashiRN — and this may be the naive question:

How much of the oral variability is the SNAC absorption window and how much is dose, because the two get conflated constantly?

Reporting back.

Follow-up: moving the tablet to the moment I wake, before anything else, was the whole fix. The dose never changed.